Long before the gradual withdrawal of international HIV funding exposed the fragility of Nigeria’s HIV response, Akwa Ibom and Rivers states had enacted laws intended to prevent such a crisis.
The laws recognised that donor assistance would not last forever and envisaged a future in which governors provided political leadership, governments financed programmes from domestic resources, local councils coordinated community interventions, and legal protections encouraged people living with HIV to seek treatment without fear of discrimination.
On paper, the laws offered a blueprint for sustainability. However, a PREMIUM TIMES investigation found little publicly available evidence that several of the statutory mechanisms operated as intended during the period under review, even as donor-supported community services began disappearing in both states.
The findings raise a critical question: if institutions specifically created to sustain the HIV response are not fully functional before donors leave, what happens when external funding eventually disappears?
The council that should lead HIV response
In Akwa Ibom, the HIV/AIDS Control Agency Law establishes the State Council on HIV/AIDS as the highest policy-making body responsible for coordinating the state’s HIV response.
Its composition reflects the importance attached to the epidemic. The governor chairs the council, while the deputy governor serves as vice-chairperson. Other members include the Secretary to the State Government, the Head of Service, commissioners from key ministries and the Director-General of the State Agency for the Control of AIDS (SACA).
Governor Umo Eno of Akwa Ibom state (CREDIT: Pastor Umo Eno on X)
Under the law, the council is responsible for providing political leadership, mobilising funding, coordinating partnerships, reviewing implementation of the state’s HIV strategic plan and ensuring that the response remains effective.
The law requires the council to meet at least once every quarter.
Yet, despite repeated requests, the Akwa Ibom government did not provide PREMIUM TIMES with records showing how many statutory meetings were held between January 2023 and June 2026, the resolutions reached at those meetings, or actions taken to prepare the state for declining international donor support.
PREMIUM TIMES also reviewed official governmentwebsites, social media pages,publications, press releases and other publicly available records but found no evidence of quarterly council meetings on HIV during the period.
When asked whether the statutory meetings had taken place, Commissioner for Health Ekem Emmanuel said Governor Umo Eno “holds meetings on HIV/AIDS” but referred questions about the number of meetings and records of deliberations to the State Agency for the Control of AIDS.
The commissioner later said he could not be expected to keep track of such meetings.
“You honestly think I will be keeping count of the meetings? I was not the Commissioner for Health in 2023,” he said.
On 7 July, PREMIUM TIMES sent a detailed 12-point enquiry to the agency’s Programme Manager, Enobong Akpan, seeking records of council meetings, budget releases, implementation of the HIV law and the state’s preparedness for shrinking donor support.
Mr Akpan acknowledged receiving the enquiry and initially promised to respond after returning to Akwa Ibom from an official meeting. Despite repeated reminders, he did not respond to the questions.
Missing grassroots structures
Akwa Ibom’s HIV law extends beyond state-level governance. It establishes Local Action Committees on HIV/AIDS across all 31 local government areas, with council chairpersons expected to lead HIV coordination at the local level.
The committees are designed to mobilise communities, coordinate prevention and treatment activities, strengthen awareness campaigns and receive financial support through local government budgets.
Effectively, they are intended to ensure that the HIV response reaches communities long before patients arrive at hospitals or clinics.
However, interviews conducted by PREMIUM TIMES with officials of the Network of People Living with HIV/AIDS in Nigeria (NEPWHAN) in Akwa Ibom, community advocates and local government stakeholders found no evidence that the committees were actively performing those statutory roles.
“We have tried engaging local governments, particularly in areas with high HIV prevalence, but the response has been poor,” Elizabeth Udo, Akwa Ibom State Coordinator of NEPWHAN, told PREMIUM TIMES.
Elizabeth Udo, Akwa Ibom State Coordinator of NEPWHAN
PREMIUM TIMES also could not independently identify recent HIV interventions directly implemented by any of the state’s 31 local governments under the framework created by the law.
Scrutiny of local government spending is further complicated by the 31 councils’ failure to publish their budgets and other fiscal documents, a practice PREMIUM TIMES previously reportedto violate the state’s fiscal responsibility law.
The situation in Rivers is similarly unclear.
Governor Siminalayi Fubara PHOTO CREDIT:Governor Fubara on X]
The Rivers State Agency for the Control of AIDS Law establishesgovernance structures intended to sustain political commitment, mobilise domestic financing and coordinate the HIV response through a Governor’s Committee on AIDS, a State Council on HIV/AIDS and Local Government Action Committees.
Those institutions were expected to become increasingly important as donor support declined.
However, when PREMIUM TIMES requested records on 7 July showing whether the statutory structures remained functional during the donor transition period, the Rivers State Agency for the Control of AIDS did not respond.
Its Programme Manager, Naaziga Francis, initially indicated that he preferred an in-person interview. But when a PREMIUM TIMES reporter travelled to the agency’s office in Port Harcourt, Mr Francis declined to answer the questions.
“I am just a civil servant. Those questions you have asked will have political consequences,” he said.
PREMIUM TIMES also visited the Rivers State Ministry of Health.Officials explained that the prolonged political crisis in the state meant no commissioner had been appointed, while the permanent secretary had retired.
Repeated telephone calls, text messages and WhatsApp messages sent to the state’s Commissioner for Information, Honour Sirawoo, were not answered before publication.
Law still waiting for assent
Beyond questions about governance and financing, another layer of protection remains incomplete.
Across Nigeria, fear of discrimination continues to discourage some people from testing for HIV, disclosing their status or remaining in treatment.
Although the National HIV and AIDS Anti-Discrimination Actprohibits discrimination against people living with HIV, health experts and human rights advocates argue that state-level laws remain important because they can provide clearer implementation mechanisms, assign responsibilities to local institutions and improve access to redress.
Akwa Ibom has attempted to enact such legislation for years.
The State House of Assembly first passedan HIV Anti-Stigma Bill in 2021. Despite repeated calls for then-Governor Udom Emmanuel to sign it, the bill lapsed after failing to receive gubernatorial assent before the Assembly completed its tenure.
Lawmakers passed the legislation againin September 2024, but nearly two years later, it still awaits the governor’s assent.
For people like Grace, Mercy, Victoria and Peter, whose experiences are at the centre of this investigation, the delay represents more than legislative bureaucracy. They say it prolongs an environment in which people living with HIV continue to experience discrimination in workplaces, families and communities.
Ms Udo said NEPWHAN members continue to report workplace discrimination, family rejection, denial of inheritance and gender-based violence linked to their HIV status.
“The government should urgently assent to the anti-stigma law,” she said.
“We should not continue relying on the United States alone for HIV response while neglecting the legal protections that encourage people to seek treatment without fear.”
Rivers State has yet to enact a similar anti-stigma law, although its annual budgets have included provisions for the legislative process.
According toLawyers Alert, a legal and human rights organisation that provides legal services to vulnerable populations, including people living with HIV, the absence of enforceable state legislation weakens both public health and human rights protections.
Its Legal Adviser, Peace Okesola, said fear of discrimination discourages some people from taking HIV tests, disclosing their status, commencing treatment early or remaining in care.
“The enactment and implementation of HIV anti-stigma laws are not merely legislative exercises; they are essential public health and human rights interventions,” the organisation told PREMIUM TIMES.
Assembly promises oversight
The Chairman of the Akwa Ibom House of Assembly Committee on Health, Moses Essien, told PREMIUM TIMES that the legislature had fulfilled its constitutional responsibility by appropriating funds for the HIV response.
“The House of Assembly has exercised its constitutional power by making adequate financial appropriations in the budget for HIV/AIDS,” he said.
“Release of funds is for the appropriate agency to apply for.”
He said lawmakers had not received any formal report indicating that approved funds were withheld.
Regarding concerns about whether the State Council on HIV/AIDS had met as required by law, Mr Essien said the committee would engage the State Agency for the Control of AIDS later this year.
“We will surely direct adherence to regulations covering the agency,” he said.
On the unsigned HIV Anti-Stigma Bill, Mr Essien, who sponsored the legislation, said he recently reminded Deputy Governor Akon Eyakenyi to bring it to the governor’s attention.
He disagreed with suggestions that the Local Action Committees on HIV/AIDS were inactive.
“I won’t subscribe to the committee’s inactivity because I am aware of steps taken by SACA regarding the functionality of all committees,” he said.
He added that Akwa Ibom had established a Local Resource Mobilisation Committee, headed by former Speaker Sam Ikon, to explore domestic financing options as donor support declines.
“As an Assembly that is concerned with the welfare of our people, we will make more budgetary provisions for HIV/AIDS in the next budget,” he added.
Beyond budgets, behind every statistic
The unanswered questions at the heart of this investigation extend beyond government paperwork.
Why were HIV appropriations identified by PREMIUM TIMES not reflected in available budget implementation records? Have the statutory governance structures established under state laws been operating as required? What concrete measures have Rivers and Akwa Ibom taken to sustain HIV services as donor funding declines? And how will the governments finance community-based interventions that patients and advocates say have disappeared?
For people living with HIV, these are not abstract questions of governance.
They determine whether a missed clinic appointment triggers a follow-up phone call, whether medicines reach patients who are too afraid to be seen at HIV clinics, whether newly diagnosed adolescents find support instead of isolation, and whether decades of progress against one of Nigeria’s most persistent public health challenges can survive a changing funding landscape.
Across the three parts of this investigation, PREMIUM TIMES found a widening gap between the structures established to sustain the HIV response and the experiences of people who depend on them.
Budgets reviewed by PREMIUM TIMES show that funds were appropriated. Laws enacted by both states created institutions intended to provide political leadership, sustainable financing and community coordination. Government officials insist efforts are being made.
Yet critical questions about implementation, accountability and preparedness remain unanswered.
Grace’s family still remembers a woman who fought to preserve her dignity until she believed the system created to protect her had failed her.
Her story, and those of countless others, point to the human cost of that uncertainty. Behind every unaccounted-for appropriation, delayed anti-stigma law and unanswered question about statutory institutions are people whose survival depends not only on antiretroviral medicines, but also on governments fulfilling the responsibilities they have already written into law.
Editor’s Note: *The names marked with asterisks have been changed to protect the privacy and identities of vulnerable individuals featured in this report.
This reporting was supported by the Centre for Journalism Innovation and Development (CJID).
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
A Nigerian pharmaceutical company, Fidson Healthcare Plc, has been selected to develop and manufacture a generic version of baloxavir marboxil, an antiviral medicine used to treat influenza.
The selection makes Fidson one of 11 manufacturers across nine countries chosen under a voluntary licensing agreement between the Medicines Patent Pool (MPP) and Swiss pharmaceutical company Roche.
The company disclosed this in a press release signed by its media contact, Tope Akindele. The MPP, a United Nations-backed public health organisation, also announced the sublicence agreements on 25 September.
The selected manufacturers are from Brazil, China, India, Indonesia, Malaysia, Nigeria, Uganda, Ukraine and Vietnam. The MPP said the arrangement is intended to “diversify supply pathways for influenza treatment, support regional production, and strengthen preparedness for future outbreaks and pandemics.”
What it means for Fidson, Nigeria
The selection makes Fidson one of the manufacturers that would develop, manufacture and supply generic versions of baloxavir in 129 countries covered by the licence, subject to regulatory authorisation.
The agreement also gives selected manufacturers access to technical data, reference products for bioequivalence studies and other support to facilitate product development and regulatory approval.
The MPP said it selected the manufacturers following an open Expression of Interest process and an assessment of their technical and regulatory capacities and commitment to producing quality-assured baloxavir products.
The organisation said having manufacturers in different regions would help build production capacity closer to the populations the medicines are intended to serve and strengthen the resilience of global supply.
For Nigeria, the selection places a local pharmaceutical manufacturer in a global effort to expand production of an influenza antiviral while strengthening domestic and regional pharmaceutical manufacturing capacity.
Selection strengthens Africa’s role
Fidson’s Managing Director and Chief Executive Officer, Biola Adebayo, described the selection as a validation of the company’s commitment to quality-assured pharmaceutical manufacturing and innovation.
“Being selected by the Medicines Patent Pool as a sublicensee under the Roche-MPP voluntary licensing programme for baloxavir marboxil is both an honour and a validation of Fidson’s longstanding commitment to quality-assured pharmaceutical manufacturing, innovation, and improving healthcare outcomes,” Mr Adebayo said.
He said the partnership would allow the company to contribute to efforts to strengthen regional health security and preparedness for future health emergencies.
“As an African healthcare company, we are proud to contribute to global efforts aimed at strengthening regional health security, enhancing preparedness for future health emergencies, and ensuring that life-saving medicines reach the patients who need them most,” he said.
Mr Adebayo said the partnership also demonstrated the growing role of African manufacturers in the global health ecosystem.
He said Fidson would work with Roche, the MPP and other stakeholders to support broader access to baloxavir across eligible markets.
The announcement came as global leaders gathered in New York for the United Nations General Assembly to discuss pandemic prevention, preparedness and response.
The MPP said the licensing arrangement is designed to build manufacturing capacity before, rather than during, a health emergency.
Charles Gore, Executive Director of the MPP, said the organisation would work with the selected manufacturers on product development and regulatory approval, aiming to make quality-assured generic baloxavir available as quickly as possible.
“By combining global manufacturing capacity with regionally focused production, we are helping build a more geographically diverse and resilient supply base for the future,” Mr Gore said.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Non-communicable diseases (NCDs) such as heart disease, diabetes and dementia accounted for 74 per cent of global deaths in 2023, up from 58 per cent in 2000, according to the latest estimates released by the World Health Organisation(WHO).
The findings, contained in the WHO’s latest Global Health Estimates released on Friday, show that although global life expectancy has largely recovered from the disruption caused by the COVID-19 pandemic, the world’s disease burden is increasingly shifting towards chronic illnesses and mental health conditions.
According to the report, global life expectancy reached 73.3 years in 2023, almost returning to the 73.4 years recorded in 2019 before the pandemic. However, healthy life expectancy, which measures the number of years people live in good health, recovered more slowly, reaching 62.8 years in 2023, still 0.4 years below its pre-pandemic level.
The WHO noted that eight of the world’s 10 leading causes of death were NCDs in 2023, highlighting a long-term global shift away from communicable diseases.
Cardiovascular diseases remain leading killer
The report identified cardiovascular diseases as the leading cause of death and disease burden worldwide.
It said ischaemic heart disease alone caused approximately 9.5 million deaths and 210 million disability-adjusted life years (DALYs) in 2023. DALYs measure years of healthy life lost due to illness, disability or premature death.
While many parts of the world have made significant progress in reducing the burden of ischaemic heart disease since 2000, the WHO reported rising individual-level risks in the Western Pacific and South-East Asia regions, highlighting persistent inequalities in cardiovascular health outcomes.
The organisation also reported substantial increases in the burden of other chronic diseases.
According to the report, the risk of dying from diabetes has risen considerably since 2000, particularly in South-East Asia.
Alzheimer’s disease and dementia have also become more prominent.
Dementia rose from the 19th leading cause of death globally in 2000 to the fifth in 2023, while deaths linked to the condition tripled during the period.
Mental health concerns
The WHO also highlighted the growing impact of mental health conditions on global health.
Between 2019 and 2023, the global age-standardised DALY rate increased by approximately 20 per cent for depressive disorders and nearly 45 per cent for anxiety disorders.
Together, depression and anxiety accounted for an estimated 110 million years of healthy life lost through premature death and disability in 2023.
The report further showed changing patterns in drug use disorders across regions.
Between 2000 and 2023, the WHO Region of the Americas recorded the largest increases in mortality risk and healthy life loss associated with drug use disorders, while the Western Pacific region experienced substantial declines.
Speaking further on the findings, Alani Labrique, Director of WHO’s Department of Data, Digital Health, Analytics and AI, described rising life expectancy as one of public health’s greatest achievements.
However, Mr Labrique noted that the next challenge is ensuring that the additional years people live are spent in good health, while health systems adapt to the changing needs of ageing populations and the growing burden of chronic diseases.
He said the estimates provide countries with evidence on how patterns of death and disease burden are changing over time, helping governments shape health policies, strengthen digital and data infrastructure, and improve their ability to generate insights needed for targeted health interventions.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.